Latest News

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry; and Sina Nikayin, MD, assistant professor of psychiatry, are featured in the first episode of a four-part Double Take video miniseries on depression from the New England Journal of Medicine.

Ebony Dix, MD, assistant professor of psychiatry, spoke to Yale Medicine about treating patients who suffer from Long COVID, which physicians say is difficult to diagnose.

Samuel Wilkinson, MD, associate professor of psychiatry and associate director of the Yale Depression Research Program, writes in Psychology Today about the history of ketamine, its use to treat depression, and how it compares to esketamine.

Henrique Oliva, MD, PhD, postdoctoral associate; Gustavo A. Angarita, MD, MHS, assistant professor of psychiatry, and Yale colleagues conducted comprehensive meta-analysis on spine density as it relates to substance use. The findings were published in Molecular Psychiatry.

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry and director of the Yale Depression Research Program, spoke to CNN about the use of ketamine to treat anxiety and depression.

Samuel T. Wilkinson, MD, associate professor of psychiatry, is author of the new book "Purpose: What Evolution And Human Nature Imply About the Meaning of Our Existence?"

Samuel Wilkinson, MD, associate professor of psychiatry, writes about achievement and maintaining relationships in Time.

Gerard Sanacora, MD, PhD (left), George D. and Esther S. Gross Professor of Psychiatry, and Samuel Wilkinson, MD, associate professor of psychiatry, have received $12.6 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for the study, “Comparative Effectiveness of Racemic Ketamine versus S-Ketamine (Spravato) for Depression.”

John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology; and Irina Esterlis, PhD, associate professor of psychiatry, are first and senior authors, respectively, of a review published in Proceedings of the National Academy of Sciences Perspective that considers what scientists have learned from studies of ketamine and to suggest future directions for the optimization of rapid-acting antidepressant treatment.